Cochrane · systematic review · CD000234
Beta‐blocker supplementation of standard drug treatment for schizophrenia
Shek, E, Bardhan, S, Cheine, MV, et al. · Cochrane Database of Systematic Reviews · 2001 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 16.7%Very low 0 · 0%Low 5 · 83.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Beta‐blockers compared to Placebo for People with Schizophrenia
Population: People with Schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: 1. Leaving the study early ‐ Short term Beta‐blockers vs Placebo | RR 1.62 [0.92, 2.83] | 8 studies · 274 participants | Low Downgraded: risk of bias, imprecision |
Global state: 2. Relapse ‐ short term Beta‐blockers vs Placebo | RR 3.12 [0.34, 28.36] | 2 studies · 68 participants | Low Downgraded: imprecision |
Adverse effects: 1. Death ‐ short term Beta‐blockers vs Placebo | no estimate extracted | 9 studies · 282 participants | Ungraded |
Adverse effects: 1. Death ‐ medium term Beta‐blockers vs Placebo | no estimate extracted | 1 study · 20 participants | Low Downgraded: risk of bias, imprecision |
Adverse effect: 2. General ‐ Short term Beta‐blockers vs Placebo | RR 5.42 [0.27, 107.2] | 1 study · 48 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: 3. Specific ‐ cardiovascular ‐ short term Beta‐blockers vs Placebo | RR 1.63 [0.7, 3.84] | 8 studies · 274 participants | Low Downgraded: risk of bias, imprecision |